Watch NNVC. Know when insiders buy.
One email the day a filing lands. Free.
NNVC
NANOVIRICIDES, INC.
1.32
+0.03 +2.33%
USD · close Nov 6
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $28.6MP/E —DIV YIELD —FCF YIELD -25.79%REV TTM —NET INCOME −$8.1MNET DEBT $1.5M52W 0.85 – 1.86SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Mar 31 | — | — | — | −$2M | −$2M | — | -0.09 | −$1.9M | $0 | −$1.9M | May 15 |
| Q2 2026 · Dec 31 | — | — | — | −$2.2M | −$2.2M | — | -0.11 | −$2M | −$1 | −$2M | May 15 |
| Q1 2026 · Sep 30 | — | — | — | −$1.8M | −$1.8M | — | -0.10 | −$1.6M | $84K | −$1.7M | May 15 |
| Q4 2025 · Jun 30derived | — | — | — | −$2.1M | −$2.1M | — | -0.13 | −$1.7M | $10K | −$1.7M | Sep 29 |
| Q3 2025 · Mar 31 | — | — | — | −$2.2M | −$2.2M | — | -0.14 | −$2M | $0 | −$2M | May 15 |
| Q2 2025 · Dec 31 | — | — | — | −$2.1M | −$2M | — | -0.14 | −$2.2M | $0 | −$2.2M | May 15 |
| Q1 2025 · Sep 30 | — | — | — | −$3.2M | −$3.1M | — | -0.23 | −$2.6M | $47K | −$2.6M | May 15 |
| Q4 2024 · Jun 30derived | — | — | — | −$2.4M | −$2.4M | — | -0.19 | −$1.5M | $98K | −$1.6M | Sep 29 |
| Q3 2024 · Mar 31 | — | — | — | −$1.9M | −$1.9M | — | -0.16 | −$1.9M | $45K | −$2M | May 15 |
| Q2 2024 · Dec 31 | — | — | — | −$2.2M | −$2.1M | — | -0.18 | −$1.7M | $5K | −$1.7M | May 15 |
| Q1 2024 · Sep 30 | — | — | — | −$2M | −$2M | — | -0.17 | −$1.2M | $8K | −$1.2M | May 15 |
| Q4 2023 · Jun 30derived | — | — | — | −$3.7M | −$3.6M | — | -0.31 | −$1.5M | $3K | −$1.5M | Sep 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jun 30 | — | — | −$9.6M | −$9.5M | — | -0.63 | −$8.5M | $57K | −$8.5M | — | — |
| FY2024 · to Jun 30 | — | — | −$8.5M | −$8.3M | — | -0.70 | −$6.3M | $157K | −$6.5M | — | — |
| FY2023 · to Jun 30 | — | — | −$8.9M | −$8.6M | — | -0.74 | −$5.7M | $152K | −$5.8M | — | — |
| FY2022 · to Jun 30 | — | — | −$8.1M | −$8.1M | — | -0.70 | −$5.9M | $324K | −$6.2M | — | — |
| FY2021 · to Jun 30 | — | — | −$8.7M | −$8.8M | — | -0.81 | −$8.2M | $239K | −$8.5M | — | — |
| FY2020 · to Jun 30 | — | — | −$8M | −$13.4M | — | -2.39 | −$6.7M | $9K | −$6.7M | — | — |
Every number comes from NANOVIRICIDES, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.